Bora CDMO Bora CDMO

X
[{"orgOrder":0,"company":"Resilia Pharmaceuticals","sponsor":"Pelle Ventures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Resilia Pharmaceuticals Acquires License to Commercialize Solace\u2122 Eczema Cream in the United States","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Resilia Pharmaceuticals

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Resilia is proud to offer patients an effective and safe product like Solace Cream, previously available by prescription. Solace Cream is formulated to help control eczema flares and keep future eczema flares dormant longer by utilizing essential skin building blocks.

            Lead Product(s): Terbinafine

            Therapeutic Area: Dermatology Product Name: Solace

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pelle Ventures

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition October 25, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY